Effectiveness of the Use of the PICSI Dish (Hyaluronan Microdot) in the Selection of Sperm for Intracytoplasmic Sperm Injection (ICSI)
Launched by BIOCOAT · Aug 25, 2008
Trial Information
Current as of April 24, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • IVF patients who require the ICSI procedure and whose care is being managed by the clinical and scientific staff of the participating groups, will be included in the study.
- Exclusion Criteria:
- * IVF patients who do not require the ICSI procedure will be excluded from the study. In addition the following groups of patients will also be excluded:
- • Patients using testicular sperm.
- • Patients using donor sperm.
- • Patients where the female partner is over 40 years of age
- • Patients who have an initial HBA score less than or equal to 2%
- • Patients who have a sperm count less than or equal to 10,000 motile sperm per ml.
- • Patients who produce less than 4 Metaphase II oocytes
Trial Officials
Kathryn Worrilow, Ph.D.
Study Director
Biocoat
About Biocoat
Biocoat is a leading innovator in the development of advanced biocompatible materials for medical applications, specializing in the creation of hydrophilic coatings that enhance the performance of medical devices. With a strong commitment to improving patient outcomes, Biocoat leverages cutting-edge technology and rigorous research to provide solutions that reduce friction, enhance lubricity, and promote patient safety. The company collaborates closely with clinical and regulatory partners to ensure that its products meet the highest standards of quality and efficacy, positioning itself as a trusted sponsor in the clinical trial landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seattle, Washington, United States
Laguna Hills, California, United States
San Ramon, California, United States
Atlanta, Georgia, United States
Atlanta, Georgia, United States
Chicago, Illinois, United States
Syracuse, New York, United States
Abington, Pennsylvania, United States
Providence, Rhode Island, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials